Clinical Trials
7 trialsNCT04601584 2024-03-06
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
AO GENERIUM
Phase 1/2 Unknown
NCT04309084 2023-02-16
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Celularity Incorporated
Phase 1 Unknown
NCT05001386 2022-03-17
ESAAC
Hospices Civils de Lyon
Phase NA Unknown
NCT05155215 2021-12-13
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1/2 Unknown
NCT03373019 2017-12-14
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Fudan University
Phase 2 Unknown
NCT03340155 2017-11-13
BioUV2017
Medical University of Graz
Phase NA Unknown
NCT00324597 2013-09-17
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Unknown